Anaesthetics

Topical Anaesthetic Products and Formulations

EMLA™

EMLA™ is a topical anaesthetic cream containing lidocaine 2.5% and prilocaine 2.5%. Both ingredients are amide local anaesthetics that reduce nerve impulse conduction, helping numb intact skin before selected procedures. Practitioners should refer to the applicable product labelling for approved indications and application requirements [1]. Prescribing and procurement requirements for EMLA™ depend on the jurisdiction and product registration. Practitioners should review applicable prescribing rules, product documentation, and supplier credentials before deciding where to source. The Med Supply Solutions support team may assist with general product information and documentation inquiries.

Why Pre-Procedure Anaesthesia Matters

Patient Comfort Supports the Treatment Experience

An appropriately selected pre-procedure anaesthetic may reduce discomfort during treatments involving dermal fillers, microneedling, and other superficial dermatological procedures. This can improve treatment tolerance without always requiring a separate anaesthetic injection. However, suitability depends on the formulation, treatment area, and approved use [3].

One Category Supports Multiple Services

A topical anaesthetic for injectables may also be relevant to other services, including microneedling and selected laser procedures. However, formulations are not necessarily interchangeable across treatments. For pre-filler numbing, mesotherapy injections, and microneedling, practitioners should consider the product's labeled indications, skin condition, application requirements, and infection-control procedures.

How Topical Anaesthetics Are Used

Application technique and timing depend on the formulation and intended procedure. The cited U.S. prescribing information for EMLA™ specifies application to intact skin under an occlusive dressing for at least one hour before procedures such as venipuncture or intravenous catheter placement. Some procedures may require longer application, and practitioners should follow the product instructions [1]. A typical professional workflow includes:

• Cleaning and drying the treatment area before application
• Applying the manufacturer-specified amount to intact skin
• Using an occlusive dressing where the product instructions require it
• Leaving the cream in place for the recommended application period
• Removing the product completely before beginning the procedure

Product strength, treatment area, patient age, skin condition, and application duration each affect systemic absorption and the resulting anaesthetic effect. Dose and timing should not be assumed to carry over between numbing products, even within the same drug class.

Anaesthetic Safety Profile

Topical anaesthetics are generally well tolerated when used as directed, though they are not risk-free. With lidocaine-prilocaine preparations, common local reactions include transient erythema, pallor or blanching, and oedema at the application site [1]. Excessive application area, dose, or contact time can increase systemic absorption, particularly when topical anaesthetics are applied to damaged or inflamed skin. Reported complications of lidocaine/prilocaine toxicity include central nervous system toxicity, cardiovascular toxicity, and methaemoglobinaemia [2]. Prilocaine-containing products warrant particular attention because prilocaine can cause methaemoglobinaemia, a condition in which haemoglobin becomes less effective at carrying oxygen. Risk is greater with excessive dosing, prolonged exposure, very young age, damaged skin, or concomitant medicines that also promote methemoglobin formation [1][2]. Known hypersensitivity to amide-type local anaesthetics or other formulation components is a contraindication to EMLA™ use [1].

Regulatory Status

Regulatory requirements for topical anaesthetics vary by formulation and jurisdiction. EMLA™ and other lidocaine/prilocaine products may be subject to prescription, dispensing, or professional-use restrictions depending on the market. Practices should verify each product's regulatory classification, approved indications, and applicable sourcing requirements. Storage and shipping conditions must also follow the relevant product instructions.

Topical Anaesthetic Wholesale: Sourcing Checks

Before pursuing topical anaesthetic wholesale arrangements, practices should verify supplier credentials, the product's regulatory classification, applicable prescribing requirements, and documentation supporting its identity. Storage and transport conditions should be checked against the specific product label rather than assuming cold-chain handling is required. The cited lidocaine/prilocaine cream labelling, for example, specifies controlled room-temperature storage [1]. Consider pricing and purchasing volumes only after you have established product suitability and regulatory requirements. When comparing numbing cream wholesale options, review packaging, expiry information, batch traceability, and any documentation needed for the intended clinical use.

Frequently Asked Questions

What is the best topical anaesthetic for injectables?

There is no single best numbing cream for injectables. Practitioners should consider the intended procedure, skin condition, and any local anaesthetics already present in the injectable product. When multiple local anaesthetic preparations are used, their combined exposure must be considered [1].

How should practices interpret lidocaine/prilocaine concentrations on product labels?

Combination anaesthetic creams should be evaluated according to the concentration of each active ingredient. EMLA™ contains lidocaine 2.5% and prilocaine 2.5%, which together provide a 5% concentration of local anaesthetic ingredients. This should not be confused with a cream containing 5% lidocaine alone.

What should practices inspect when topical anaesthetic products arrive?

Receiving checks should include product identity, active ingredients, strength, expiry date, batch or lot number, and packaging condition. Practices should also confirm that any required storage and transport conditions were maintained and investigate discrepancies before clinical use.

How can practices obtain topical anaesthetics?

Sourcing requirements depend on the product's regulatory status and the destination market. For prescription preparations such as EMLA™ in markets where a prescription is required, practices should follow the applicable professional procurement rules. The Med Supply Solutions support team may assist with product information and documentation inquiries.

Citations

[1] U.S. Food and Drug Administration. EMLA Cream (Lidocaine 2.5% and Prilocaine 2.5%): Prescribing Information. 2018. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/019941s021lbl.pdf. [2] Tran, Anh N, and John Y Koo. “Risk of systemic toxicity with topical lidocaine/prilocaine: a review.” Journal of drugs in dermatology : JDD vol. 13,9 (2014): 1118-22. [3] Sobanko, Joseph F et al. “Topical anesthetics for dermatologic procedures: a review.” Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.] vol. 38,5 (2012): 709-21. doi:10.1111/j.1524-4725.2011.02271.x